Nexalin Technology, Inc.
No SEC Form 4 filings for $NXL in the last 30 days.
See all $NXL insider activity →U.S. stocks fell Thursday, with the Dow Jones dropping 200 points. Micron (MU) reported Q4 revenue of $54.23B, beating estimates. Nexalin (NXL) and Stablecoin (SDEV) shares surged, while Corteva (CTVA) and NewGenIvf (NIVF) shares declined. Oil and gold prices rose, while European and Asian markets closed mixed.
Nexalin Technology (NXL) signed a 10-year exclusive distribution agreement with Inovanexa Medical Technologies for Brazil and six other South American countries. The deal includes a 100-device commercialization program, local manufacturing, and revenue-sharing. Nexalin Sync, approved for anxiety, depression, and insomnia, will be distributed across 300 million people.
RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning NXL (Nexalin Technology, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent NXL coverage spans corporate actions, technology and earnings.
Deal expands market reach, driving strong short‑term rally.
The agreement creates a recurring royalty stream and opens a 300‑million‑person market, likely driving upside for the stock.
Upcoming trial could be a catalyst; success may drive share price higher.
Positive but hypothesis‑generating data may boost investor interest but limited immediate price impact.
Executive exit with modest severance; limited immediate price impact.
AlphAI scores every news story that mentions NXL with an AI model for sentiment and relevance, and aggregates insider trades from Nexalin Technology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
U.S. stocks fell Thursday, with the Dow Jones dropping 200 points. Micron (MU) reported Q4 revenue of $54.23B, beating estimates. Nexalin (NXL) and Stablecoin (SDEV) shares surged, while Corteva (CTVA) and NewGenIvf (NIVF) shares declined. Oil and gold prices rose, while European and Asian markets closed mixed.
3 min readNexalin Technology (NXL) signed a 10-year exclusive distribution agreement with Inovanexa Medical Technologies for Brazil and six other South American countries. The deal includes a 100-device commercialization program, local manufacturing, and revenue-sharing. Nexalin Sync, approved for anxiety, depression, and insomnia, will be distributed across 300 million people.
2 min readRedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.
2 min readNexalin Technology (NXL) reported new cognitive improvements in Alzheimer's patients using its Gen-2 SYNC DIFS device, based on a secondary analysis of trial data. 10 of 20 participants showed meaningful improvements in memory and language. The company plans a U.S. pilot study incorporating these findings. NXL stock is currently at $5.44, down 12.12%.
2 min readNexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Direct ors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2026, Carolyn Shelton departed from her role as Senior Vice President of Quality, Regulatory, and Clinical A
1 min readNexalin Technology (NXL) announced a 1-for-30 reverse stock split, effective August 28, 2026, to comply with Nasdaq's bid-price rule. Trading will resume on August 31 under the same ticker. The company develops neurostimulation products for mental health.
1 min readNexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 21, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Investor purchased from
1 min readNexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On August 19, 2026, Nexalin Technology, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional investor (the “Investor”), pursuant
1 min readNexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Maters to a Vote of Security Holders. The annual meeting (the “Annual Meeting”) of the stockholders of Nexalin Technology, Inc. (the “Company”) was convened at 10:00 a.m. Eastern time on August 11, 2026. Of the 22,011,302 shares of the Company’s common sto
2 min readNexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On July 28, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Third Amendment to Office Lease (the “Third Amendment”) with Nutex HQ LLC (“Landlord”), which amends that certain Office Lease from 2012, as previously
2 min read